AR and renal cell carcinoma: Similarly, studies have shown that targeting AR in both RCC cells (HKC-5, 786-O, 786-P, and SW839) and xenografts (HKC-5 and 786-O) inhibits cell migration and invasion by modulating HIF2a/VEGF signaling by recruiting vascular endothelial cells 290.